Precision Medicine

Molecular testing improves patient outcomes and reduces healthcare costs by personalizing treatments to each individual patient based on genomic insights.

Patients often react differently to drugs, even apart from factors such as age or weight. An effective treatment for one person may not work for someone else or may cause adverse reactions. The main cause of this variation is the inherent diversity of our genetic makeup. Understanding individual differences in the human genome can help physicians select and tailor treatments – the right drug at the right time for the right patient. This is the foundation of Precision Medicine.

Precision Medicine draws on pharmacogenomics – the study of how a person’s genetic makeup affects the body’s response to drugs – to enable development of new therapeutics and to help doctors customize treatments to achieve the best results. Instead of a trial-and-error approach, physicians can use each patient’s genomic information to choose the most effective medication with the fewest side effects. For example, companion diagnostics are now routinely used to assess the potential benefits of targeted therapies for many types of cancer patients.

The key to Precision Medicine is the close connection between therapeutics and diagnostics. Precision Medicine benefits both the patient and society as a whole, enabling more effective treatments and more efficient use of resources in healthcare systems.
Economic and Social Effects

Billions of dollars are spent each year on prescriptions for drugs and other therapies that turn out to be ineffective or even harmful to particular individuals. In the United States, studies have shown that the most frequently prescribed medications show the desired effect in fewer than 60% of patients.¹

Without significant improvements in the ability to target the right treatment to the most appropriate patients, these adverse effects are likely to intensify and become more frequent in an aging population, with treatment costs rising as a result. The number of complications and deaths associated with medicines has already seen a significant increase since mid-1990.²

Views on Precision Medicine

Precision Medicine is already a reality. The genomic knowledge base is constantly growing and the essential techniques in molecular diagnostics are readily available. The U.S. Food and Drug Administration (FDA) has identified diagnostic biomarkers for about 240³ existing drugs that target a variety of diseases and has approved roughly 43 companion diagnostics.⁴ Given the significant benefits of Precision Medicine, this number is expected to grow.

- **Oncology**: The detection of mutations in genes such as PIK3CA, FGFR, KRAS, EGFR, JAK2, BRAF or BCR-ABL helps to predict how patients suffering from various malignancies respond to specific therapies. Many new cancer therapies offer great promise, but they are very costly and only effective in patients who either have or lack a specific gene mutation. In the case of colorectal cancer, where therapy with so-called monoclonal antibodies can cost up to $60,000 per treatment cycle, only patients without mutations (approx. 60% of the patient population) in the KRAS gene are likely to benefit from the targeted medication. Many biomarkers can also help to guide treatments of other cancers such as lung, pancreatic, brain, thyroid, leukemia, etc. Traditionally a biomarker is approved based on where in the body it originated for example PIK3CA in metastatic breast cancer. With the advancement in drug development and immune-oncology research biomarkers known as pan-cancer biomarkers are emerging. In 2017, the FDA granted the first approval of a cancer treatment based on a common biomarker rather than the location of the solid tumor.

- **Tissue typing**: In tissue transplants (such as bone marrow transplants), donors are linked to recipients who offer the best genetic match, thus reducing the risk of an adverse immune response.

In addition to medical and economic demands, the growing use of Precision Medicine is driven by the economics of pharmaceutical R&D. By understanding and optimizing the risk-benefit profile of drugs for specific types of patients, Precision Medicine can improve the development of new therapeutics. The challenges in drug development include:

---

**Examples of drugs’ efficacy rates**

<table>
<thead>
<tr>
<th>Drugs for treatment of:</th>
<th>Ineffective in % of patients:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression</td>
<td>38%</td>
</tr>
<tr>
<td>Asthma</td>
<td>40%</td>
</tr>
<tr>
<td>Diabetes</td>
<td>43%</td>
</tr>
<tr>
<td>Arthritis</td>
<td>50%</td>
</tr>
<tr>
<td>Alzheimer’s</td>
<td>70%</td>
</tr>
<tr>
<td>Cancer</td>
<td>75%</td>
</tr>
</tbody>
</table>

Cost of development: On average, developing a new drug costs about $1.25 billion and is associated with significant risks. Using molecular tests, pharmaceutical companies can design more efficient clinical trials and increase the likelihood of approval of new drugs.

Compensation costs: Unexpected adverse side effects also pose high legal risks, even if cause and effect are not proven. For instance, in the case of J&J anti-psychotic Risperdal settlements equaled $8 billion.

Loss of value: Risperdal was one of J&J top-selling drugs. At its peak (2004) it accounted for 5% of J&J total revenue that year. Whilst this fine was downgraded by a federal judge in 2020 the impact to J&J reputation was long lasting from 2012 until today.

Product life cycle: By combining drugs with genetic tests, pharmaceutical companies can expand the indications of drugs following initial approval and thus enhance their life cycle.

Second chance: Many drug candidates fail in a late development stage or during the approval process because their efficacy and safety cannot be proven across large, diverse patient groups. Some of these “fallen angels” can still be approved for treatment of individual patient groups with a specific genetic makeup.

Pricing: As the efficacy of drugs rise, pharmaceutical companies can change existing price models.

While Precision Medicine is already a reality, several challenges have to be addressed:

Regulatory obligations: In some countries it can take up to 15 years to obtain governmental approval for new diagnostics or drugs. This discourages companies from developing new treatments for small population groups. Nevertheless, regulatory bodies such as the FDA are increasingly integrating genetic testing into pharmaceutical product labels. To date, the FDA has published biomarker information on 406 biomarkers. A guideline for the development of companion diagnostics is now also available from the FDA.

Doctors’ behavior: Many physicians lack sufficient knowledge about Precision Medicine and therefore continue with traditional treatments.

Healthcare system: Opposing interests in the healthcare and political systems delay decisions regarding best practice and reimbursement – and thus the introduction of innovations. Often, the lag in reimbursement policies and systems encourages the treatment of diseases rather than their prevention through the early use of diagnostics. However, as healthcare costs in developed nations are predicted to grow up to 20% of GDP in the near future, Precision Medicine represents an increasingly attractive way to reduce costs by eliminating ineffective treatments.

Reimbursement policies: Often, reimbursement levels for new diagnostics are based on technical aspects of the diagnostic method and don’t reflect the clinical value of a test. Decision making is too slow and is non-transparent. This hampers necessary investments in the development of novel diagnostic tests. However, there is a shift in thinking to value-based reimbursement of diagnostics among some health payers.

Biomarker research: Personalized therapies rely upon biomarkers that are indicative for certain physical conditions or processes and allow for the personalization of treatment strategies. Given the enormous complexity and scope of molecular information in the human body, the identification and validation of biomarkers continues to pose significant challenges to biomedical research.
QIAGEN and Precision Medicine

With a broad offering of Sample to Insight solutions, QIAGEN is a global leader in Precision Medicine. The company’s proven expertise in companion diagnostic (CDx) development means they are uniquely positioned to give pharma partners access to a breadth of IVD solutions across multiple analytes (plasma, DNA and RNA) and multiple technologies (from qPCR, dPCR & Next Generation Sequencing (NGS)). Utilizing this breadth of technology QIAGEN is the only partners which has the flexibility to tailor a CDx program to any partners needs. Using this customized offering coupled with a comprehensive launch readiness framework and large global footprint in molecular labs, they support the entire development process – from idea through to global commercialization.

QIAGEN is also a pioneer in minimally invasive liquid biopsy methods for companion diagnostics with CE-IVD and FDA approvals. Amid the explosion of genomic data from next-generation sequencing, QIAGEN is the industry’s leader in bioinformatics to interpret complex biological data and provide actionable insights for clinical decision support.

- With more than 25 collaborations and over 30 projects with major pharmaceutical companies, QIAGEN is developing and offering more companion diagnostics than any other company. Partnerships include collaborations with Amgen, Array BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Eli Lilly, Novartis and many others.
- QIAGEN’s test portfolio for Precision Medicine applications covers a broad range of biomarkers. The company has a proven track record of nine (9) CE-IVD and FDA approvals. Its product offering includes regulatory approved assays for oncogenes such as KRAS, PIK3CA, FGFR, BRAF and EGFR.
- With leading technologies for extraction and processing of nucleic acids from body fluids, QIAGEN is pioneering the development of companion diagnostics based on minimally invasive liquid biopsies. In Europe, QIAGEN markets the first companion diagnostic for a cancer drug based on this technology – the *therascreen* EGFR Plasma RGQ PCR Kit paired with IRESSA from AstraZeneca and more recently with *therascreen* PIK3CA plasma RGQ PCR kit co-approved with PIGRAY from Novartis.
- QIAGEN’s bioinformatics solutions allow users to generate valuable molecular insights from highly complex genomic data. QIAGEN Clinical Insight, a clinical decision support system tailored for the needs of clinical labs, can be integrated into the company’s next-generation sequencing workflow.
- QIAGEN offers a broad range of technology platforms for development of companion diagnostics, including qPCR, digital PCR and NGS panels (developed for use on Illumina platforms as part of a 15 year partnership).

Underpinning the excellence in IVD development of Companion diagnostics QIAGEN has developed a unique program – Day One lab Readiness – which is not only an important tool for global commercialization but also vital to ensure day-one access for patients to innovative CDx tests at the time of drug approval.

---